BLOOD FLOW RESTRICTED RESISTANCE TRAINING ATTENUATES MYOSTATIN GENE EXPRESSION ON A PATIEINIT WITH ONCLUSION BODY MYOSITIS

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorSANTOS, A. R.
dc.contributor.authorNEVES JR., M. T.
dc.contributor.authorGUALANO, B.
dc.contributor.authorLAURENTINO, G. C.
dc.contributor.authorJR, A. H. Lancha
dc.contributor.authorUGRINOWITSCH, C.
dc.contributor.authorLIMA, F. R.
dc.contributor.authorAOKI, M. S.
dc.date.accessioned2014-09-30T15:10:04Z
dc.date.available2014-09-30T15:10:04Z
dc.date.issued2014
dc.description.abstractInclusion body myositis is a rare idiopathic inflammatory myopathy that produces extreme muscle weakness. Blood flow restricted resistance training has been shown to improve muscle strength and muscle hypertrophy in inclusion body myositis. Objective: The aim of this study was to evaluate the effects of a resistance training programme on the expression of genes related to myostatin (MSTN) signalling in one inclusion body myositis patient. Methods: A 65-year-old man with inclusion body myositis underwent blood flow restricted resistance training for 12 weeks. The gene expression of MSTN, follistatin, follistatin-like 3, activin II B receptor, SMAD-7, MyoD, FOXO-3, and MURF-2 was quantified. Results: After 12 weeks of training, a decrease (25%) in MSTN mRNA level was observed, whereas follistatin and follistatin-like 3 gene expression increased by 40% and 70%, respectively. SMAD-7 mRNA level was augmented (20%). FOXO-3 and MURF-2 gene expression increased by 40% and 20%, respectively. No change was observed in activin II B receptor or MyoD gene expression. Conclusions: Blood flow restricted resistance training attenuated MSTN gene expression and also increased expression of myostatin endogenous inhibitors. Blood flow restricted resistance training evoked changes in the expression of genes related to MSTN signalling pathway that could in part explain the muscle hypertrophy previously observed in a patient with inclusion body myositis.
dc.description.indexPubMed
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado de Sao Paulo, Brazil (FAPESP) [08/58415-3, 07/53318-7, 08/51090-1]
dc.description.sponsorshipCAPES (Brazil)
dc.description.sponsorshipCNPq (Brazil)
dc.description.sponsorshipFAPESP (Brazil)
dc.identifier.citationBIOLOGY OF SPORT, v.31, n.2, p.121-124, 2014
dc.identifier.doi10.5694/20831862.1097479
dc.identifier.issn0860-021X
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/7887
dc.language.isoeng
dc.publisherINST SPORT
dc.relation.ispartofBiology of Sport
dc.rightsopenAccess
dc.rights.holderCopyright INST SPORT
dc.subjectGDF-8
dc.subjectmuscle hypertrophy
dc.subjectmRNA
dc.subjectreal-time PCR
dc.subject.othervascular occlusion
dc.subject.otherskeletal-muscle
dc.subject.otherexercise
dc.subject.otheratrophy
dc.subject.otherhumans
dc.subject.otherdisuse
dc.subject.othermass
dc.subject.otherhypertrophy
dc.subject.otherintensity
dc.subject.othermechanism
dc.subject.wosSport Sciences
dc.titleBLOOD FLOW RESTRICTED RESISTANCE TRAINING ATTENUATES MYOSTATIN GENE EXPRESSION ON A PATIEINIT WITH ONCLUSION BODY MYOSITIS
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.author.externalSANTOS, A. R.:Univ Sao Paulo, Sch Phys Educ & Sport, BR-03828000 Sao Paulo, Brazil
hcfmusp.author.externalNEVES JR., M. T.:Univ Sao Paulo, Sch Med, Div Rheumatol, BR-03828000 Sao Paulo, Brazil
hcfmusp.author.externalLAURENTINO, G. C.:Univ Sao Paulo, Sch Phys Educ & Sport, BR-03828000 Sao Paulo, Brazil
hcfmusp.author.externalJR, A. H. Lancha:Univ Sao Paulo, Sch Phys Educ & Sport, BR-03828000 Sao Paulo, Brazil
hcfmusp.author.externalUGRINOWITSCH, C.:Univ Sao Paulo, Sch Phys Educ & Sport, BR-03828000 Sao Paulo, Brazil
hcfmusp.author.externalAOKI, M. S.:Univ Sao Paulo, Sch Arts Sci & Humanities, BR-03828000 Sao Paulo, Brazil
hcfmusp.citation.scopus22
hcfmusp.contributor.author-fmusphcBRUNO GUALANO
hcfmusp.contributor.author-fmusphcFERNANDA RODRIGUES LIMA
hcfmusp.description.beginpage121
hcfmusp.description.endpage124
hcfmusp.description.issue2
hcfmusp.description.volume31
hcfmusp.origemWOS
hcfmusp.origem.pubmed24899776
hcfmusp.origem.scopus2-s2.0-84899668984
hcfmusp.origem.wosWOS:000338390600006
hcfmusp.publisher.cityWARSAW 45
hcfmusp.publisher.countryPOLAND
hcfmusp.relation.referenceAoki MS, 2009, MUSCLE NERVE, V40, P992, DOI 10.1002/mus.21426
hcfmusp.relation.referenceArmand AS, 2003, DEV DYNAM, V227, P256, DOI 10.1002/dvdy.10306
hcfmusp.relation.referenceArnardottir S, 2003, J REHABIL MED, V35, P31, DOI 10.1080/16501970306110
hcfmusp.relation.referenceDrummond MJ, 2010, EUR J APPL PHYSIOL, V108, P771, DOI 10.1007/s00421-009-1279-z
hcfmusp.relation.referenceForbes D, 2006, J CELL PHYSIOL, V206, P264, DOI 10.1002/jcp.20477
hcfmusp.relation.referenceFry AC, 2004, SPORTS MED, V34, P663, DOI 10.2165/00007256-200434100-00004
hcfmusp.relation.referenceGomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198
hcfmusp.relation.referenceGualano B, 2010, MED SCI SPORT EXER, V42, P250, DOI 10.1249/MSS.0b013e3181b18fb8
hcfmusp.relation.referenceJespersen JG, 2011, SCAND J MED SCI SPOR, V21, P215, DOI 10.1111/j.1600-0838.2009.01044.x
hcfmusp.relation.referenceKarabulut M, 2010, EUR J APPL PHYSIOL, V108, P147, DOI 10.1007/s00421-009-1204-5
hcfmusp.relation.referenceKim J.S., 2005, AM J PHYSIOL-ENDOC M, V288, P1110
hcfmusp.relation.referenceKubo K, 2006, J APPL BIOMECH, V22, P112
hcfmusp.relation.referenceLaurentino GC, 2012, MED SCI SPORT EXER, V44, P406, DOI 10.1249/MSS.0b013e318233b4bc
hcfmusp.relation.referenceLee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098
hcfmusp.relation.referenceMcPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0
hcfmusp.relation.referenceMurton AJ, 2010, CURR OPIN CLIN NUTR, V13, P249, DOI 10.1097/MCO.0b013e3283374d19
hcfmusp.relation.referenceNeedham M, 2007, LANCET NEUROL, V6, P620, DOI 10.1016/S1474-4422(07)70171-0
hcfmusp.relation.referenceNeedham M, 2008, J CLIN NEUROSCI, V15, P1350, DOI 10.1016/j.jocn.2008.01.011
hcfmusp.relation.referenceNeves Jr M., 2010, J VIS EXP, V5, P1894
hcfmusp.relation.referencePainelli VD, 2009, AUTOIMMUN REV, V8, P355, DOI 10.1016/j.autrev.2008.11.008
hcfmusp.relation.referencePetrella JK, 2008, J APPL PHYSIOL, V104, P1736, DOI 10.1152/japplphysiol.01215.2007
hcfmusp.relation.referencePhillips SM, 2009, J APPL PHYSIOL, V107, P645, DOI 10.1152/japplphysiol.00452.2009
hcfmusp.relation.referenceRatamess NA, 2009, MED SCI SPORT EXER, V41, P687, DOI 10.1249/MSS.0b013e3181915670
hcfmusp.relation.referenceRoth SM, 2003, EXP BIOL MED, V228, P706
hcfmusp.relation.referenceSpector SA, 1997, MUSCLE NERVE, V20, P1242, DOI 10.1002/(SICI)1097-4598(199710)20:10<1242::AID-MUS6>3.0.CO;2-C
hcfmusp.relation.referenceWilloughby DS, 2004, MED SCI SPORT EXER, V36, P574, DOI 10.1249/01.MSS.0000121952.71533.EA
hcfmusp.relation.referenceWitt CC, 2008, EMBO J, V27, P350, DOI 10.1038/sj.emboj.7601952
hcfmusp.relation.referenceYokokawa Y, 2008, BIOSCI TRENDS, V2, P117
hcfmusp.relation.referenceZhang P, 2007, MED HYPOTHESES, V69, P310, DOI 10.1016/j.mehy.2006.11.043
hcfmusp.relation.referenceZhu XY, 2004, CYTOKINE, V26, P262, DOI 10.1016/j.cyto.2004.03.007
hcfmusp.remissive.sponsorshipCAPES
hcfmusp.remissive.sponsorshipCNPq
hcfmusp.remissive.sponsorshipFAPESP
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublication5c94f430-a9d0-4b0e-b23a-9a9b1fc12a9a
relation.isAuthorOfPublication1b3fa590-9944-46c1-a48b-c3d8a6336bc3
relation.isAuthorOfPublication.latestForDiscovery5c94f430-a9d0-4b0e-b23a-9a9b1fc12a9a
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_SANTOS_BLOOD_FLOW_RESTRICTED_RESISTANCE_TRAINING_ATTENUATES_MYOSTATIN_GENE_2014.PDF
Tamanho:
239.98 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - LIM/17